Dana R. Abendschein, Ph.D.

Associate Professor
Internal Medicine
Cell Biology and Physiology

Molecular Cell Biology Program

  • 314-362-8925

  • 314-362-8930

  • 314-747-3971

  • 8015

  • CSRB 9920

  • dabendsc@DOM.wustl.edu

  • http://cardiology.wustl.edu/research2/dana-abendschein-phd.html

  • vascular biology, thrombosis, myocardial infarction, stroke, diabetes, unstable plaque

  • Inhibition of coagulation and platelet activation without bleeding, and identification of unstable plaque

Research Abstract:

Research in this translational physiology laboratory focuses primarily on development of novel antithrombotic approaches for use during acute myocardial infarction and stroke where vascular injury is an underlying cause. Over the last 30 years, using a variety of experimental animal models, the lab has facilitated development of many conjunctive therapeutics for fibrinolysis and angioplasty including platelet glycoprotein IIb/IIIa inhibitors, hirudin, direct factor Xa inhibitors, and tissue factor pathway inhibitor. More recent studies have focused on development of novel antithrombotics, fusion proteins, and nanoparticulate delivery systems that could be used conjointly with or independent of a supporting vascular stent to provide targeted and safe antithrombotic therapy after vascular injury. The lab is also interested in how the metabolic syndrome and diabetes affect the time course and type of therapeutics required to achieve passivation of the injured arterial wall. Trainees are responsible for conducting hands-on experiments in intact animal models of disease and vascular injury; developing strategies to image vessels, thrombosis, and associated inhibitors; using assays for coagulation protease activities, histopathologic analysis of therapeutic efficacy; and computing the statistical significance of data; and composing results of studies for presentation and publication.

Selected Publications:

Moeckel D, Jeong S, Sun X, Broekman J, Nguyen A, Marcus AJ, Robson S, Chen R, Abendschein DR.(2014). Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without bleeding risk. Science: Translational Medicine, 6(248):248ra105. PMID: 25100739.

Marsh JN, Hu G, Scott MJ, Zhang H, Goette MJ, Gaffney PJ, Caruthers SD, Wickline SA, Abendschein D, Lanza GM. (2011). A fibrin-specific thrombolytic nanomedicine approach to acute ischemic stroke, Nanomedicine (Lond), 6(4):605-615. PMID: 21506686.

Liu Y, Abendschein D, Woodard GE, Rossin R, McCommis K, Zheng J, Welch MJ, Woodard PK. (2010). Molecular Imaging of Atherosclerotic Plaque with (64)Cu-Labeled Natriuretic Peptide and PET. J Nucl Med. 51(1):85-91. PMID: 20008978.

Dietrich HH, Abendschein DR, Moon SH, Nayeb-Hashemi N, Mancuso DJ, Jenkins CM, Kaltenbronn KM, Blumer KJ, Turk J, Gross RW. (2010). Genetic ablation of calcium-independent phospholipase A2 causes hypercontractility and markedly attenuates endothelium-dependent relaxation to acetylcholine. AJP-Heart and Circ Physiol 298: H2208-20. PMID: 20382858.

Almutairi A, Rossin R, Shokeen M, Hagooly A, Ananth A, Capoccia B, Guillaudeu S, Abendschein D, Anderson CJ, Welch MJ, and Frechet JMJ. (2009). Biodegradable dendritic positron emitting nanoprobes for the non invasive imaging of angiogenesis. PNAS USA 106:685-690. PMID 19129498

Zheng J, Ochoa E, Misselwitz B, Yang D, El Naqa I, Woodard PK, Abendschein D. (2008). Targeted contrast agent helps to monitor advanced plaque during progression: an MRI study in rabbits. Invest Radiol 43:49-55. PMID 18097277.

Choi ET, Khan MF, Leidenfrost JE, et al. Beta3- integrin mediates smooth muscle cell accumulation in neointima after carotid ligation in mice. (2004). Circulation 109:1564-1569.

Last Updated: 11/17/2014 11:47:17 AM

Effect of a novel apyrase that decreases platelet activation without bleeding on myocardial infarction
Back To Top

Follow us: